Matthew Biegler
Stock Analyst at Oppenheimer
(3.42)
# 2,411
Out of 4,675 analysts
399
Total ratings
39.6%
Success rate
3.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics | Reiterated: Buy | $30 → $14 | $3.89 | +259.90% | 8 | Aug 14, 2026 | |
| BMEA Biomea Fusion | Reiterated: Buy | $9 | $1.59 | +466.04% | 15 | Aug 6, 2026 | |
| GILD Gilead Sciences | Rated: Hold | n/a | $146.74 | - | 16 | Jun 15, 2026 | |
| CTMX CytomX Therapeutics | Rated: Hold | n/a | $3.29 | - | 12 | Jun 15, 2026 | |
| ARVN Arvinas | Rated: Hold | n/a | $9.34 | - | 17 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Rated: Hold | n/a | $40.04 | - | 20 | Jun 15, 2026 | |
| ORIC ORIC Pharmaceuticals | Rated: Hold | n/a | $13.46 | - | 23 | Jun 15, 2026 | |
| RLAY Relay Therapeutics | Rated: Hold | n/a | $19.76 | - | 18 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Rated: Hold | n/a | $10.43 | - | 23 | Jun 15, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 | $2.03 | +244.83% | 9 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $26.09 | +91.64% | 23 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $3.76 | +139.36% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $26.27 | +6.59% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.06 | - | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $865 | $828.50 | +4.41% | 13 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $16.71 | +169.30% | 2 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $9.14 | +140.70% | 4 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.84 | +290.63% | 22 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.20 | +263.64% | 13 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.44 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.98 | n/a | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $22.71 | n/a | 13 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11.04 → $4.14 | $0.44 | n/a | 12 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.36 | n/a | 15 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $0.1525 | n/a | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.7748 | n/a | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.59 | n/a | 6 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $50 | $1.50 | n/a | 15 | Feb 17, 2022 |
OnKure Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $30 → $14
Current: $3.89
Upside: +259.90%
Biomea Fusion
Aug 6, 2026
Reiterated: Buy
Price Target: $9
Current: $1.59
Upside: +466.04%
Gilead Sciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $146.74
Upside: -
CytomX Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $3.29
Upside: -
Arvinas
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $9.34
Upside: -
IDEAYA Biosciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $40.04
Upside: -
ORIC Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $13.46
Upside: -
Relay Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $19.76
Upside: -
Olema Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $10.43
Upside: -
Allogene Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $7
Current: $2.03
Upside: +244.83%
May 14, 2026
Reiterated: Buy
Price Target: $50
Current: $26.09
Upside: +91.64%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $3.76
Upside: +139.36%
May 13, 2026
Reiterated: Buy
Price Target: $28
Current: $26.27
Upside: +6.59%
May 12, 2026
Rated: Hold
Price Target: n/a
Current: $10.06
Upside: -
Apr 30, 2026
Reiterated: Buy
Price Target: $865
Current: $828.50
Upside: +4.41%
Mar 27, 2026
Reiterated: Buy
Price Target: $45
Current: $16.71
Upside: +169.30%
Mar 6, 2026
Reiterated: Buy
Price Target: $22
Current: $9.14
Upside: +140.70%
Dec 8, 2025
Reiterated: Buy
Price Target: $15
Current: $3.84
Upside: +290.63%
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $2.20
Upside: +263.64%
May 14, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.44
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: n/a
Current: $2.98
Upside: n/a
Dec 9, 2024
Maintained: Buy
Price Target: $160
Current: $22.71
Upside: n/a
Aug 14, 2023
Maintained: Buy
Price Target: $11.04 → $4.14
Current: $0.44
Upside: n/a
Jul 31, 2023
Rated: Hold
Price Target: n/a
Current: $16.36
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $18
Current: $0.1525
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.7748
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $2.59
Upside: n/a
Feb 17, 2022
Maintained: Buy
Price Target: $8 → $50
Current: $1.50
Upside: n/a